Select Page
Club de lecture l'Actuel

For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

Management of HIV/HCV co-infection

With Dr. Réjean Thomas and Dr. Jürgen Rockstroh

 

PROGRAM EXCERPT

HIGHLIGHTS

  • Effective HIV treatment reduces the risk of fibrosis progression
  • Integrase inhibitors and direct-acting agents
  • HCV among MSM
  • New EACS guideline on the treatment of HCV

This activity is supported
by an educational grant from:

800px-Merck_Logo.svg

SUMMARY

PARTICIPANTS

Managing HIV/HCV co-infection

Drug/drug interactions are a major challenge in managing patients co-infected with HIV and HCV.

The arrival of molecules that are better tolerated by the liver, in particular non-boosted integrase inhibitors, which have no interactions with currently available direct-acting agents (DAAs), make them ideal partners for treating with all oral hepatitis C treatments.

Particular attention should be paid to the rise in cases of HCV in the MSM and HIV-positive MSM communities.

Under the new EACS guidelines presented by Dr. Rockstroh in Barcelona (2015), hepatitis C treatment is recommended early (from F2, or even F1 and F0), and independently of liver condition, depending on patient-specific considerations, especially if they have a high risk of transmission, immune vulnerability or extrahepatic manifestations.

Réjean Thomas, MD, Dhc

Réjean Thomas, MD, Dhc

Interviewer

CEO – Founder
Clinique médicale l’Actuel:
Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM) Québec, Canada

Dr. Jürgen Rockstroh, MD, PhD

Dr. Jürgen Rockstroh, MD, PhD

Interviewee

Professor of Medicine
Head of the HIV Outpatient Clinic
University of Bonn,
 Germany

AND THE SUPPORT OF:

COMPLETE PROGRAM

You must be logged in to view the complete program
DISCLOSURE
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.


Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation with:
Advisory boards : AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare

Dr Jürgen Rockstroh, MD, PhD has a financial interest/relationship or affiliation with: Abbvie, BMS, Janssen, Gilead, Merck, ViiV


Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.